Aldeyra Therapeutics, Inc.
A securities class action has been filed in the USDC – MA. against Aldeyra Therapeutics, Inc. (ALDX) (“Aldeyra” or the “Company”) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Aldeyra securities between March 17, 2022 through June 20, 2023, both dates inclusive (the “Class Period”).
Aldeyra, a biotechnology company, develops and commercializes medicines for immune-mediated diseases. The Company is currently developing ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
- the ADX2191 NDA did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness;
- as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form;
- accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times, thereby harming investors.
If you purchased Aldeyra securities during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.